Positive Two-Year Data Boost Prospects For Vivus' Qnexa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Two-year Qnexa data released by Vivus Sept. 21 could serve to bolster the long-term prospects for the weight-loss drug as they address areas of concern identified during recent reviews of obesity drugs by FDA's Endocrinologic and Metabolic Drugs Advisory Committee - including higher efficacy standards and the need to show benefit on co-morbidities associated with weight loss